BioXcel Therapeutics, Inc. (BTAI)

Market Cap	23.96M
Revenue (ttm)	2.28M
Net Income (ttm)	-71.00M
Shares Out	40.74M
EPS (ttm)	-1.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,885
Open	0.590
Previous Close	0.603
Day's Range	0.550 - 0.601
52-Week Range	0.500 - 4.170
Beta	0.29
Analysts	Strong Buy
Price Target	5.00 (+750.34%)
Earnings Date	Nov 14, 2024

About BTAI

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI
• Website: https://www.bioxceltherapeutics.com

Financial Performance

In 2023, BioXcel Therapeutics's revenue was $1.38 million, an increase of 268.00% compared to the previous year's $375,000. Losses were -$179.05 million, 8.02% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 750.34% from the latest price.

Price Target

$5.0

(750.34% upside)

Analyst Consensus: Strong Buy